Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Status epilepticus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RAISE
  • Sponsors Marinus Pharmaceuticals

Most Recent Events

  • 17 Oct 2024 According to a Marinus Pharmaceuticals media release, Clinical data from this study were presented as an oral presentation at Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California.
  • 11 Oct 2024 According to a Marinus Pharmaceuticals media release, company announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California.
  • 26 Sep 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top